Cystectomy Latest Advances

Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.

Journal: The Journal of urology

Published: June 22, 2026

Correction: How safe is teaching radical cystectomy?

Journal: World journal of urology

Published: June 15, 2026

Dementia and Frailty Impact Postoperative Care Trajectories and Burden among Older Adults Undergoing Radical Cystectomy for Bladder Cancer.

Journal: medRxiv : the preprint server for health sciences

Published: June 12, 2026

Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer.

Journal: BMJ open

Published: June 11, 2026

Editorial Comment on "Perioperative Predictors of Length of Stay and Readmission After Simple Cystectomy And Urinary Diversion in Non-Ambulatory Adults With Neurogenic Bladder".

Journal: Urology

Published: June 10, 2026

External Validation of A Decision Tree Model for Predicting Cancer-Specific Mortality After Radical Cystectomy: A Multi-Center Study in South-East Spain.

Journal: Archivos espanoles de urologia

Published: June 10, 2026

The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas.

Journal: Fertility and sterility

Published: June 09, 2026

Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Journal: Oncology and therapy

Published: June 09, 2026

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.

Journal: bioRxiv : the preprint server for biology

Published: June 04, 2026

Comment to: "Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type".

Journal: World journal of urology

Published: June 01, 2026

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 31, 2026

Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 29, 2026

Cystectomy Latest Advances

Latest Advances in Cystectomy Procedure

Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.

Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.

Correction: How safe is teaching radical cystectomy?

Correction: How safe is teaching radical cystectomy?

Dementia and Frailty Impact Postoperative Care Trajectories and Burden among Older Adults Undergoing Radical Cystectomy for Bladder Cancer.

Dementia and Frailty Impact Postoperative Care Trajectories and Burden among Older Adults Undergoing Radical Cystectomy for Bladder Cancer.

Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer.

Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer.

Editorial Comment on "Perioperative Predictors of Length of Stay and Readmission After Simple Cystectomy And Urinary Diversion in Non-Ambulatory Adults With Neurogenic Bladder".

Editorial Comment on "Perioperative Predictors of Length of Stay and Readmission After Simple Cystectomy And Urinary Diversion in Non-Ambulatory Adults With Neurogenic Bladder".

External Validation of A Decision Tree Model for Predicting Cancer-Specific Mortality After Radical Cystectomy: A Multi-Center Study in South-East Spain.

External Validation of A Decision Tree Model for Predicting Cancer-Specific Mortality After Radical Cystectomy: A Multi-Center Study in South-East Spain.

The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas.

The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas.

Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.

Comment to: "Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type".

Comment to: "Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type".

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.

Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.